- Therma Bright Inc. (THRM) shared an update for its AcuVid COVID-19 Rapid Antigen Saliva Test
- It has continued to communicate with the U.S. Food and Drug Administration (FDA) regarding an EUA application
- Ridge Global and FDA consultants are helping to accelerate the review of the application
- Therma Bright has fielded several potential sales inquiries for the antigen test
- It will bring it to eastern European markets and anywhere that accepts its CE mark
- Therma Bright Inc. (THRM) is down 6.06 per cent and is trading at $0.15 per share as of 10:55 a.m. ET
Therma Bright Inc. (THRM) has shared an update for its AcuVid COVID-19 Rapid Antigen Saliva Test.
Therma Bright stated it has continued to communicate with the U.S. Food and Drug Administration (FDA) regarding a EUA application for its rapid antigen saliva test. On top of this, Therma Bright has been working with Ridge Global and FDA consultants to find a way to accelerate the review of the application.
“We thank our shareholders for their continued patience and support. The FDA EUA review process is rigorous and thorough, as are all regulatory reviews, and therefore patience is required,” Rob Fia, CEO of Therma Bright, said.
The company is expecting to receive additional feedback from the FDA.
In other news, Therma Bright has fielded several potential sales inquiries for the AcuVid COVID-19 Rapid Antigen Saliva Test. It discusses an order using its self-certification CE mark to sell in the eastern European market and any other countries that accept the mark.
Therma Bright is a medical diagnostic and device technology company focused on providing quality, innovative solutions that address certain medical and healthcare challenges. The company’s initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare.
Therma Bright Inc. (THRM) is down 6.06 per cent and is trading at $0.15 per share as of 10:55 a.m. ET.
